Affimed N.V. (NASDAQ: AFMD) stock jumped 4.27% on Friday to $1.22 against a previous-day closing price of $1.17. With 3.9 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.2500 whereas the lowest price it dropped to was $1.1350. The 52-week range on AFMD shows that it touched its highest point at $5.10 and its lowest point at $1.03 during that stretch. It currently has a 1-year price target of $7.60. Beta for the stock currently stands at 2.36.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AFMD was up-trending over the past week, with a rise of 7.96%, but this was up by 10.91% over a month. Three-month performance dropped to -17.57% while six-month performance fell -60.65%. The stock lost -71.36% in the past year, while it has lost -1.61% so far this year. A look at the trailing 12-month EPS for AFMD yields -0.61 with Next year EPS estimates of -0.74. For the next quarter, that number is -0.20. This implies an EPS growth rate of 2.90% for this year and -27.00% for next year.
Float and Shares Shorts:
At present, 149.34 million AFMD shares are outstanding with a float of 137.53 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.79 million, which was 2.54% higher than short shares on Sep 14, 2022. In addition to Dr. Adi Hoess as the firm’s CEO, MD & Member of Management Board, Mr. Angus W. Smith serves as its CFO & Member of Management Board.
Through their ownership of 68.45% of AFMD’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 32.74% of AFMD, in contrast to 16.21% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in AFMD with 5.72% of the stake, 683 Capital Management LLC holds 8,350,000 shares worth 8,350,000. A second-largest stockholder of AFMD, BlackRock Fund Advisors, holds 6,841,971 shares, controlling over 4.69% of the firm’s shares. Baker Bros. Advisors LP is the third largest shareholder in AFMD, holding 6,596,830 shares or 4.52% stake. With a 2.17% stake in AFMD, the iShares Russell 2000 ETF is the largest stakeholder. A total of 3,169,037 shares are owned by the mutual fund manager. The Pictet – Biotech, which owns about 1.75% of AFMD stock, is the second-largest Mutual Fund holder. It holds 2,554,686 shares valued at 3.17 million. Pictet – Global Megatrend Selecti holds 1.16% of the stake in AFMD, owning 1,696,973 shares worth 2.1 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AFMD since 10 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AFMD analysts setting a high price target of $12.33 and a low target of $1.88, the average target price over the next 12 months is $7.20. Based on these targets, AFMD could surge 910.66% to reach the target high and rise by 54.1% to reach the target low. Reaching the average price target will result in a growth of 490.16% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AFMD will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$0.49 being high and -$0.68 being low. For AFMD, this leads to a yearly average estimate of -$0.56. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Affimed N.V. surprised analysts by $0.06 when it reported -$0.11 EPS against a consensus estimate of -$0.18. The surprise factor in the prior quarter was $0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.15 and the low estimate is -$0.26. The average estimate for the next quarter is thus -$0.19.